FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022786166> ?p ?o ?g. }

• W2022786166 endingPage "114" @default.
• W2022786166 startingPage "99" @default.
• W2022786166 abstract "Multidrug resistance (MDR) remains one of the major reasons for the reductions in efficacy of many chemotherapeutic agents in cancer therapy. As a classical MDR phenotype of human malignancies, the adenosine triphosphate binding cassette (ABC)-transporter P-glycoprotein (MDR1/P-gp) is an efflux protein with aberrant activity that has been linked to multidrug resistance in cancer. For the reversal of MDR by RNA interference (RNAi) technology, an U6-RNA gene promoter-driven expression vector encoding anti-MDR1/P-gp short hairpin RNA (shRNA) molecules was constructed (abbreviated pDNA-iMDR1-shRNA). This study explored the feasibility of using Pluronic P123-conjugated polypropylenimine (PPI) dendrimer (P123-PPI) as a carrier for pDNA-iMDR1-shRNA to overcome tumor drug resistance in breast cancer cells. P123-PPI functionalized with anti-CD44 monoclonal antibody (CD44 receptor targeting ligand) (anti-CD44-P123-PPI) can efficiently condense pDNA into nanocomplexes to achieve efficient delivery of pDNA, tumor specificity and long circulation. The in vitro studies methodically evaluated the effect of P123-PPI and anti-CD44-P123-PPI on pDNA-iMDR1-shRNA delivery and P-gp downregulation. Our in vitro results indicated that the P123-PPI/pDNA and anti-CD44-P123-PPI/pDNA nanocomplexes with low cytotoxicity revealed higher transfection efficiency compared with the PPI/pDNA nanocomplexes and Lipofectamine™ 2000 in the presence of serum. The nanocomplexes loaded with pDNA-iMDR1-shRNA against P-gp could reverse MDR accompanied by the suppression of MDR1/P-gp expression at the mRNA and protein levels and improve the internalization and cytotoxicity of Adriamycin (ADR) in the MCF-7/ADR multidrug-resistant cell line. BALB/c nude mice bearing MCF-7/ADR tumor were utilized as a xenograft model to assess antitumor efficacy in vivo. The results demonstrated that the administration of anti-CD44-P123-PPI/pDNA-iMDR1-shRNA nanocomplexes combined with ADR could inhibit tumor growth more efficiently than ADR alone. The enhanced therapeutic efficacy of ADR may be correlated with increased accumulation of ADR in drug-resistant tumor cells. Consequently, these results suggested that the use of pDNA-iMDR1-shRNA-loaded nanocomplexes may be a promising gene delivery strategy to reverse MDR and improve the effectiveness of chemotherapy." @default.
• W2022786166 created "2016-06-24" @default.
• W2022786166 creator A5023154058 @default.
• W2022786166 creator A5069269815 @default.
• W2022786166 creator A5072357652 @default.
• W2022786166 creator A5088022415 @default.
• W2022786166 date "2015-03-01" @default.
• W2022786166 modified "2023-09-30" @default.
• W2022786166 title "Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery" @default.
• W2022786166 cites W120814930 @default.
• W2022786166 cites W1483781798 @default.
• W2022786166 cites W1560355462 @default.
• W2022786166 cites W1717624658 @default.
• W2022786166 cites W1968274640 @default.
• W2022786166 cites W1982464351 @default.
• W2022786166 cites W1984105689 @default.
• W2022786166 cites W1990017773 @default.
• W2022786166 cites W1992998779 @default.
• W2022786166 cites W1995170769 @default.
• W2022786166 cites W1995323554 @default.
• W2022786166 cites W1999327728 @default.
• W2022786166 cites W2013782445 @default.
• W2022786166 cites W2022317048 @default.
• W2022786166 cites W2022865936 @default.
• W2022786166 cites W2023389405 @default.
• W2022786166 cites W2025111276 @default.
• W2022786166 cites W2027736008 @default.
• W2022786166 cites W2036459378 @default.
• W2022786166 cites W2039551093 @default.
• W2022786166 cites W2040006430 @default.
• W2022786166 cites W2046070477 @default.
• W2022786166 cites W2048555387 @default.
• W2022786166 cites W2051950678 @default.
• W2022786166 cites W2053118297 @default.
• W2022786166 cites W2060661415 @default.
• W2022786166 cites W2061568968 @default.
• W2022786166 cites W2061698895 @default.
• W2022786166 cites W2063171868 @default.
• W2022786166 cites W2063557396 @default.
• W2022786166 cites W2066215258 @default.
• W2022786166 cites W2069651638 @default.
• W2022786166 cites W2071860668 @default.
• W2022786166 cites W2073166200 @default.
• W2022786166 cites W2073619242 @default.
• W2022786166 cites W2073798358 @default.
• W2022786166 cites W2079808092 @default.
• W2022786166 cites W2082368328 @default.
• W2022786166 cites W2087470472 @default.
• W2022786166 cites W2087968529 @default.
• W2022786166 cites W2089980335 @default.
• W2022786166 cites W2094341952 @default.
• W2022786166 cites W2096619102 @default.
• W2022786166 cites W2099978446 @default.
• W2022786166 cites W2100857282 @default.
• W2022786166 cites W2109247464 @default.
• W2022786166 cites W2114457955 @default.
• W2022786166 cites W2114487091 @default.
• W2022786166 cites W2117230556 @default.
• W2022786166 cites W2120162732 @default.
• W2022786166 cites W2122326980 @default.
• W2022786166 cites W2142987628 @default.
• W2022786166 cites W2149064045 @default.
• W2022786166 cites W2151760476 @default.
• W2022786166 cites W2158764445 @default.
• W2022786166 cites W2165836181 @default.
• W2022786166 cites W2166699788 @default.
• W2022786166 cites W2169678660 @default.
• W2022786166 cites W42293926 @default.
• W2022786166 doi "https://doi.org/10.1016/j.biomaterials.2014.12.030" @default.
• W2022786166 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25662500" @default.
• W2022786166 hasPublicationYear "2015" @default.
• W2022786166 type Work @default.
• W2022786166 sameAs 2022786166 @default.
• W2022786166 citedByCount "52" @default.
• W2022786166 countsByYear W20227861662015 @default.
• W2022786166 countsByYear W20227861662016 @default.
• W2022786166 countsByYear W20227861662017 @default.
• W2022786166 countsByYear W20227861662018 @default.
• W2022786166 countsByYear W20227861662019 @default.
• W2022786166 countsByYear W20227861662020 @default.
• W2022786166 countsByYear W20227861662021 @default.
• W2022786166 countsByYear W20227861662022 @default.
• W2022786166 countsByYear W20227861662023 @default.
• W2022786166 crossrefType "journal-article" @default.
• W2022786166 hasAuthorship W2022786166A5023154058 @default.
• W2022786166 hasAuthorship W2022786166A5069269815 @default.
• W2022786166 hasAuthorship W2022786166A5072357652 @default.
• W2022786166 hasAuthorship W2022786166A5088022415 @default.
• W2022786166 hasConcept C104317684 @default.
• W2022786166 hasConcept C109316439 @default.
• W2022786166 hasConcept C114851261 @default.
• W2022786166 hasConcept C133936738 @default.
• W2022786166 hasConcept C153911025 @default.
• W2022786166 hasConcept C166703698 @default.
• W2022786166 hasConcept C185592680 @default.
• W2022786166 hasConcept C190232843 @default.
• W2022786166 hasConcept C202751555 @default.
• W2022786166 hasConcept C22615655 @default.

• next